VD kommenterar Tack för ert fortsatta stöd och förtroende för Aptahem och vår läkemedelskandidat Apta-1! Den vältecknade teckningsoptionsserien TO 5, med en teckningsgrad på 95%, gör det möjligt att fortsatt hålla gott tempo i genomförandet av de planerade aktiviteterna...
Read MoreBioStock published an article on 24 March 2021 about Aptahem, which can be read in full below. Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a life-threatening condition that is relatively unknown to the...
Read MoreBioStock published an article on 10 March 2021 about Aptahem, which can be read in full below. Aptahem announced yesterday that the company has entered into a non binding Term Sheet (NBTS) with a European pharmaceutical company. The NBTS...
Read MoreAptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license terms for exclusive development, manufacturing and distribution of...
Read MoreAptahem AB (publ) announce today that the company has signed an agreement with their collaboration partner LGC Group to initiate the GMP (Good Manufacturing Practice) manufacturing of Apta-1. With this agreement, Aptahem ensures that the previously communicated schedule is...
Read MoreAptahem AB (publ) announce today that the company has received patent approval in India for patent family 1, with patent application number 6250/DELNP/2010. The patent, with the patent number 353024, covers the protection of the company’s aptamer structures. The...
Read More